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Abstract. Background: The aim of this retrospective study was
to assess whether the intratumoral microvessel density (IMD)
in primary tumour specimens had any impact on the clinical
outcome of patients with advanced epithelial ovarian cancer
treated in two Italian departments of gynaecological oncology.
Materials and Methods: The study was conducted on 101
patients who underwent initial surgery followed by platinum-
based chemotherapy (37) or paclitaxel/platinum- based
chemotherapy (64) for International Federation of Gynecology
and Obstetrics (FIGO) stage III-IV epithelial ovarian cancer.
The median follow-up of survivors from initial surgery was 65
months (range, 27 to 132 months). Paraffin-embedded sections
of primary tumour specimens were analysed for IMD by
immunohistochemistry using anti-CD34 antibodies. Results:
Progression-free survival and overall survival were significantly
better in patients with IMD ≥40 microvessels/field compared
with those with lower IMD (p=0.0105 and p=0.0065,
respectively). Cox model showed that IMD was the strongest
independent prognostic variable for both progression-free
survival (p=0.0267) and overall survival (p=0.0189).
Conclusion: An elevated IMD was associated with a
significantly better progression-free survival and overall survival
in patients with stage III-IV epithelial ovarian cancer who
underwent initial surgery followed by chemotherapy, mainly
consisting of a paclitaxel/platinum-based regimen. 
Neoangiogenesis, i.e., the development of new blood vessels
from the existing vasculature, is an essential step of solid
tumour growth and spread, and several experimental
investigations have revealed that tumour diameters, when
angiogenesis is blocked or absent, range approximately
between 0.2 mm and 2 mm (1-3). Tumour angiogenesis can
be microscopically assessed as intratumoral microvessel
density (IMD), i.e., mean value of microvessel count
obtained using a specific objective magnification with known
field diameter in three or four fields subjectively selected
from the so-called "hot spots" (4). Antibodies against a
variety of endothelial markers have been tested to stain
microvessels (4-7). 
The prognostic relevance of IMD has been long assessed
in different human malignancies, with contrasting results.
Several papers have reported that a high IMD was related
to a poor survival in patients with breast cancer (6, 8), lung
cancer (7, 9), prostate cancer (10, 11), gastric cancer (12),
colon cancer (13), endometrial cancer (14, 15) and cervical
cancer (16-19). Conversely, the multivariate analysis of
other studies has shown no relationship or a positive
relationship between IMD and the clinical outcome of
patients with breast cancer (5, 20), renal cancer (21), brain
cancer (22), endometrial cancer (23) and cervical cancer
(24). Conflicting data have been also reported for epithelial
ovarian cancer. Some authors detected that a high IMD
was a poor prognostic variable (25-33), others observed
that this parameter had no impact on survival (34-39),
others again reported that a high IMD was associated with
a better prognosis (40-43). In this paper the prognostic
relevance of IMD on primary tumour specimens from 101
patients with advanced epithelial ovarian cancer treated in
two Italian departments of gynaecological oncology, has
been investigated. 
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Materials and Methods
This retrospective study was conducted on 101 patients who
underwent initial surgery followed by platinum-based or
paclitaxel/platinum-based chemotherapy for advanced epithelial
ovarian cancer at the Departments of Gynecology and Obstetrics
of the Universities of Pisa and Torino, between March 1993 and
November 2002. 
The tumour stage and histological diagnosis of each patient
were determined according to the criteria of the International
Federation of Gynecology and Obstetrics (FIGO) and histological
typing system of the World Health Organization (WHO),
respectively. Tumours were graded as well- (G1), moderately- (G2),
or poorly-differentiated (G3). 
The evaluation of the clinical course of disease was based on
clinical examination, serum CA 125 assay, chest X-ray,
abdominal-pelvic ultrasound and computed tomography scan.
Additional investigations were performed when appropriate.
After the sixth cycle of chemotherapy the patients with no
evidence of disease at clinical, serologic, sonographic and
radiologic examinations were defined as being in clinical
complete response. Three to 5 weeks after the end of
chemotherapy a second-look surgery was usually proposed to
clinically complete responders, mostly to patients enrolled onto
clinical trials. A pathological complete response at second-look
surgery was defined as the disappearance of all macroscopic
tumour deposits with negative peritoneal washing and negative
multiple random biopsies. All patients with clinically or surgically
detectable persistent disease, as well as some pathologically
complete responders, received additional chemotherapy. 
All patients were periodically observed until they died or until
May 2005. The median follow-up of survivors from initial surgery
was 65 months (range, 27 to 132 months).
Formalin-fixed paraffin-embedded sections of primary tumour
specimens obtained from all patients were independently
analyzed for histopathological and immunohistochemical
examination by all pathologists and inconsistencies were solved
by a simultaneous review. 
Immunohistochemistry
Antibodies. Sections were incubated with the primary mouse anti-
human CD34 antibody. The incubation time was 12 h at 4ÆC.
Sections were deparaffinized in xylene and rehydrated in alcohol.
Endogenous peroxide activity was blocked by 10 min incubation in
hydrogen peroxide solution (1% hydrogen peroxide in methanol). In
order to unmask the antigens, the slides were microwaved for 10 min
in citrate buffer (10 mM, pH 6). After blocking non-specific staining
with serum, the sections were first incubated with the primary
antibody, and then with biotin-labelled secondary antibody (dilution
1:500; 30’) and avidin-biotin-complex (30’). 3-3’Diaminobenzidine
tetrahydrochloride was used as chromogen. The sections were
counterstained with haematoxylin, dehydrated and mounted.
Vascular endothelial cells were used as positive controls for
CD34. Negative controls were obtained by omitting the primary
antibody.
IMD determination was performed with the methodology
described by the International Consensus in 1996 (44). The vessels
were counted in the three most vascularized areas ("hot spots") of the
tumour and a mean value was then considered. Microvessel counts
were performed at x200 (x20 objective lens and x10 ocular lens; 
0.74 mm2 per field). A single microvessel was defined as discrete
clusters or single cells stained for CD34 and the presence of a lumen
was not required for scoring as a microvessel. The antibodies used
for tissue section immunostaining and the methodology employed for
IMD determination were the same for both centers.
Statistical methods. The SAS statistical package (release 8.2; SAS
Institute, Cary, NC, USA) was used for computations.
IMD expression was compared to the clinico-pathological
variables using median exact test and Pearson's ¯2 test (or two-
tailed Fisher's exact test when appropriate). 
The cumulative probability of progression-free survival and
overall survival from the time of initial surgery were estimated by
the product-limit method. The log-rank test was used to compare
the homogeneity of progression-free survival and overall survival
functions across strata defined by categories of prognostic variables. 
A multiple regression analysis based on the Cox proportional
hazards model was used to test jointly the relative importance of
variables as predictors of progression-free survival and overall
survival times. 
Results
The median age of the patients was 63 years (range, 25 to
80 years). The tumour stage was III in 90 patients and IV
in 11 patients. Histologically, 75 carcinomas were serous, 10
endometrioid, 11 undifferentiated and 5 mucinous. Tumour
grade was G1 in 5 patients, G2 in 15 patients and G3 in 81
patients. Residual disease after initial surgery was ≤1 cm in
23 patients and >1 cm in 78 patients. The planned
combination chemotherapy consisted of six cycles of
paclitaxel plus carboplatin in 55 patients, epidoxorubicin
plus paclitaxel plus carboplatin in 9 patients,
cyclophosphamide plus epidoxorubicin or doxorubicin plus
cisplatin in 15 patients, cyclophosphamide plus cisplatin in 2
patients, single-agent carboplatin in 19 patients, and single-
agent cisplatin in one patient. 
The IMD in primary tumour specimens ranged from 4 to
114 microvessels/field, and, the 25%, 50% and 75%
quantiles were 10, 18 and 39 microvessels/field, respectively.
No relationship was detected between IMD and the
common clinico-pathological variables (Table I).
By log-rank test progression-free survival was significantly
related to age, histological type, residual disease and IMD
(Table II). Progression-free survival was significantly better
in patients with IMD ≥40 microvessels/field compared with
those with lower IMD (p=0.0105) (Figure 1). 
By log-rank test overall survival was significantly related
to age, histological type and IMD (Table II). Overall
survival was significantly better in patients with IMD ≥40
microvessels/field compared with those with lower IMD
(p=0.0065) (Figure 2). 
Cox model showed that IMD was the strongest
independent prognostic variable for both progression-free
survival (p=0.0267) (Table III) and overall survival
(p=0.0189) (Table IV).
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Table I. Relationship between IMD and the common clinico-pathological variables in patients with advanced epithelial ovarian cancer.
IMD ( microvessels/field)
Variable No. of patients ≤10 11-18 19-39 ≥40 p-value
Age (years) 
≤63 51 16 (31.4%) 13 (25.5%) 7 (13.7%) 15 (29.4%) ns 
>63 50 16 (32.0%) 8 (16.0%) 16 (32.0%) 10 (20.0%) 
FIGO stage 
III 90 28 (31.1%) 20 (22.2%) 20 (22.2%) 22 (24.4%) ns 
IV 11 4 (36.4%) 1 (9.1%) 3 (27.3%) 3 (27.3%) 
Histology 
serous 75 24 (32.0%) 13 (17.3%) 16 (21.3%) 22 (25.3%) ns 
not serous 26 8 (30.8%) 8 (30.8%) 7 (26.9%) 3 (11.5%)
Tumour grade 
G1-G2 20 8 (40.0%) 4 (20.0%) 4 (20.0%) 4 (20.0%) ns
G3 81 24 (29.6%) 17 (21.0%) 19 (23.5%) 21 (25.9%) 
RD residual disease 
≤1 cm 23 9 (29.1%) 3 (13.0%) 4 (17.4%) 7 (30.4%) ns 
>1 cm 78 23 (29.5%) 18 (23.1%) 19 (24.4%) 18 (23.1%) 
IMD, intratumoral microvessel density; G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated ; RD, residual disease;
ns, not significant.
Table II. Variables predictive of progression-free survival and overall survival in patients with advanced epithelial ovarian cancer (univariate analysis).
Progression-free survival Overall survival 
5-year median p-value 5-year median p-value 
% (months) % (months)
Age (years)
≤63 51 25 22 0.0363 47 56 0.0221
>63 50 13 16 28 40
FIGO stage 
III 90 19 20.5 0.7572 38 45 0.7146
IV 11 23 15 40 51
Histology 
serous 75 24.5 22 0.0301 45 51 0.0242
not serous 26 0 17 18 36 
Tumor grade 
G1-G2 20 15 17 0.2632 30 35 0.0880
G3 81 20 21 40 46 
RD 
≤1 cm 23 36 27 0.0151 1 71 0.1086
>1 cm 78 14 17 33 40
IMD (microvessels/field)
≤10 32 15 16.5 0.0105 25 35 0.0065
11-19 21 11 18 21 43 
20-39 23 11 15 32 40 
≥40 25 36 36 67 not reached
G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; RD, residual disease; IMD, intratumoral microvessel density. 
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Figure 1. Progression-free survival in advanced ovarian cancer patients by intratumoral microvessel density (IMD).
Figure 2. Overall survival in advanced ovarian cancer patients by intratumoral microvessel density (IMD).
Discussion
Several authors reported that the risk of progression and
death of patients with epithelial ovarian cancer increased
with raising IMD (Table V) (25-33). Hollingsworth et al.
(25) detected that higher stage, higher average IMD at
200x and 400x magnification and highest IMD at 400x
magnification conferred worse disease-free survival in
patients with advanced epithelial ovarian cancer, and that
the lowest average IMD at 400x was the strongest predictor
of disease-free survival at multivariate analysis. An elevated
IMD (>48 microvessels/field) was a poor prognostic
indicator for overall survival at univariate analysis
(p=0.034) but not at multivariate analysis in a series of
patients with advanced disease who received a platinum-
based chemotherapy (26). By using a computer-aided
image analysis system to quantify IMD, Schoell et al. (27)
found that the endothelial area in tumour specimens of the
14 patients who survived for ≥6 years was smaller
compared with that of the 14 patients matched for stage
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Table III. Variables predictive of progression-free survival in patients with advanced epithelial ovarian cancer (Cox model).
Variable Parameter estimate Standard error Wald ¯2 p-value OR 95%CI
IMD –0.01165 0.00526 4.9087 0.0267 0.988 0.978-0.999
Age 0.50821 0.23358 4.7340 0.0296 1.662 1.052-2.627
RD 0.57650 0.29557 3.8044 0.0511 1.780 0.997-3.177
Histotype 0.33397 0.26086 1.6392 0.2004 1.397 0.838-2.329
Tumour grade –0.22221 0.27976 0.6309 0.4270 0.801 0.463-1.386
Stage 0.04845 0.39803 0.0148 0.9031 1.050 0.481-2.290
OR, Ôdds ratio; 95%CI, 95% confidence internal; IMD, intratumoral microvessel density; RD, residual disease.
Table IV. Variables predictive of overall survival in patients with advanced epithelial ovarian cancer (Cox model).
Variable Parameter estimate Standard error Wald ¯2 p-value OR 95%CI
IMD –0.01488 0.00634 5.5067 0.0189 0.985 0.973-0.998
Age 0.53605 0.25264 4.5019 0.0339 1.709 1.042-2.804
RD 0.41384 0.32108 1.6613 0.1974 1.513 0.806-2.838
Histotype 0.43549 0.27809 2.4524 0.1173 1.546 0.896- 2.666
Tumour grade –0.37682 0.29029 1.6850 0.1943 0.686 0.388-1.212
Stage –0.06123 0.46029 0.0177 0.8942 0.941 0.382-2.319
OR, odds ratio; 95%CI, 95% confidence internal; IMD, intratumoral microvessel density; RD, residual disease.
Table V. Prognostic relevance of IMD in epithelial ovarian cancer. 
Authors Ref. No. of FIGO Endothelial Correlation between high 
patients stage marker IMD and survival 
Hollingsworth et al. (25) 43 III-IV CD34 worse disease-free survival at multivariate analysis 
Gasparini et al. (26) 60 III-IV CD31 worse survival at univariate, not at multivariate 
Alvarez et al. (28) 88 I-IV vWF worse survival at univariate, not at multivariate 
Obermaier et al. (30) 63 I-III CD34 worse survival at univariate, not at multivariate 
Raspollini et al. (31) 83 III CD34 worse survival at multivariate analysis 
Goodheart et al. (32) 33 Ic CD31 worse survival at multivariate analysis 
van Diest et al. (34) 49 III-IV Ulex no correlation with survival 
Terai et al. (36) 54 I-IV CD34 no correlation with survival 
Nakajama et al. (37) 42 I-IV CD34 no correlation with survival 
Ali-Fehmi et al. (40) 118 III-IV CD34 no correlation with survival 
Chan et al. (43) 46 III-IV CD34 better survival at multivariate analysis 
Present series 101 III-IV CD34 better survival at multivariate analysis 
IMD, intratumoral microvessel density; vWF, von Willebrand Factor; Ulex, Ulex europeas lectin.
and treatment who died of disease (0.038±0.026 mm2
versus 0.110±0.034 mm2, p<0.0001). Alvarez et al. (28)
reported a median survival of 2.7 years for women with
IMD >10 microvessels/field versus 7.9 years for those with
lower microvessel count (p=0.03), but IMD did not retain
statistical significance after adjusting for stage at
multivariate analysis. Similarly, Obermair et al. (30) found
a better 5-year overall survival for the 18 patients with a
low IMD (<10 microvessels/field) compared with the 45
patients with high IMD (55% versus 24%, p=0.03), but this
angiogenic parameter failed to attain a significant value
after adjustment for the common prognostic factors, such
as patient age, tumour stage and histological grade.
Raspollini et al. (31) evaluated IMD in tissue sections from
patients with stage III, serous, poorly-differentiated
epithelial ovarian cancer who underwent primary debulking
surgery and platinum-based or paclitaxel/platinum-based
chemotherapy. An IMD >70 microvessels/ high power field
(HPF) was an independent poor prognostic variable for
both disease-free (p=0.001) and overall survival
(p<0.0005). In a further investigation, the same authors
(33) compared the IMD assessed with a computer-aided
image analysis system in 23 patients with FIGO stage III,
serous, poorly-differentiated epithelial ovarian cancer, who
were disease-free 5 years after primary surgery and
platinum-based chemotherapy, and in 10 patients matched
for stage, histological type, tumour grade and treatment,
who died of disease within one year after primary therapy.
Once again, this angiogenic parameter correlated with
survival at multivariate analysis (p=0.05).
As for early epithelial ovarian cancer, an elevated IMD
(>12 microvessels/HPF) was an independent poor
prognostic variable for disease-specific survival (hazard
ratio, 4.8; 95% confidence interval, 1.1-22; p=0.04) in 33
patients with stage Ic disease (32).
Conversely, other authors failed to detect a negative impact
of an elevated IMD on the clinical outcome of patients with
epithelial ovarian cancer (34-39) (Table V). Van Diest et al.
(34) found no correlation between IMD in primary tumour
sections and survival at either univariate or multivariate
analysis in patients with advanced disease who received
platinum-based chemotherapy. Orre et al. (35) found no
differences in IMD, determined with anti-CD31 and anti-
CD34 antibodies, among patients with different clinical
outcomes. Similarly, no relationship between IMD and
survival was observed in the series of Terai et al. (36),
Nakayama et al. (37) and Ali-Fehmi et al. (39).
Some studies have even shown a better prognosis for
patients with higher microvessel count (40-43) (Table V).
An immunohistochemical study on surgical specimens
from 105 primary ovarian cancers showed that, among
women with early disease, an elevated IMD (≥70
microvessels/HPF) was related to a better progression-free
survival (40). This association was significant only for the
patients with clear cell carcinoma. Chan et al. (42) found
that, among women with advanced disease, the median
survival was better in the 24 patients with IMD >11
microvessels/field compared with the 22 with lower
microvessel count (59.7 versus 23.9 months, p=0.001), and
that this angiogenic variable retained a significant value at
multivariate analysis. The same authors (43) reported that
patients with high IMD (>11 microvessels/field) and high
peri-tumoral mast cell infiltration had a better mean
survival than those with low IMD or low mast cell density
(80.3 versus 37.8 months, p=0.015). According to the
authors the formation of new vessels could allow the
accumulation of mast cells and release of mast cell tryptase
that is a potent fibroblast growth factor, thus, enhancing
fibroblast recruitment and fibrosis development that limits
tumour growth and spread (43, 45).
In the present study an assessment was made of the
clinical relevance of IMD in primary tumour specimens
from 101 patients with stage III-IV disease who
underwent initial surgery followed by platinum-based
chemotherapy, mainly consisting of a paclitaxel/platinum-
based regimen, in two Italian departments. Patients with
highly vascularized tumours had a significantly better
progression-free and overall survival at both univariate
and multivariate analysis, in agreement with the results of
a previous investigation of Gadducci et al. on a smaller
number of cases (41). The positive association between an
elevated IMD and a better clinical outcome might be due
to the fact that high tumour vascularity could allow a
major drug availability and greater sensitivity to paclitaxel
(41, 42). Besides a direct cytotoxic effect on tumour cells,
paclitaxel exhibits potent anti-angiogenic activity, even at
very low concentrations, by an increase in microtubule
dynamics in endothelial cells (46, 47). This anti-angiogenic
activity might be particularly relevant in highly
vascularized tumours. 
The determination of IMD shows remarkable methodo-
logical variations among different papers, especially as for
the number of hot spots counted, the definition of the
minimum criteria of a countable microvessel, the areas
and fields of magnification, and staining markers and
methods used (4, 8). These methodological variations, as
well as differences in patient characteristics and
chemotherapy regimens used, may partly explain the
contrasting results reported in the literature as for
prognostic relevance of IMD in several malignancies
including epithelial ovarian cancer. 
Large studies with well standardized pathology laboratory
procedures and with homogenous groups of patients as for
stage, histological type and treatment, are warranted to
better elucidate the prognostic relevance of IMD in
epithelial ovarian cancer.
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